Loading…
Loading…
Home › All recalls › Prescription medicine
Category
Prescription drugs recalled for contamination, potency or labelling.
Or try another category
1,991 recalls · newest first
Subpotent Drug
Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
Lack of Assurance of Sterility
Failed Dissolution Specifications
Presence of precipitate
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.
Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II,…
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II,…
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.
Presence of Foreign Tablets/Capsules
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).